Merck Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways
Business Wire India New data from DNA Damage Response (DDR) inhibitor portfolio inform development path for this promising biology Clinical trials in locally advanced head and neck cancer and advanced…